Hematopoietic malignancies demonstrate loss-of-function mutations of BAX.
暂无分享,去创建一个
S. Korsmeyer | G. Waksman | J. Meijerink | A. Slöetjes | E. Mensink | S. Korsmeyer | T. D. de Witte | T. Sedlak | K. Wang | E. Mensink | Kun Wang | T. Witte | A. Slöetjes
[1] G Waksman,et al. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[2] F Gambale,et al. Inhibition of Bax channel-forming activity by Bcl-2. , 1997, Science.
[3] M. Minden,et al. Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and Tal-1 (SCL). , 1997, Blood.
[4] S. Korsmeyer,et al. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[5] S. Ogawa,et al. Mutations and loss of expression of a mismatch repair gene, hMLH1, in leukemia and lymphoma cell lines. , 1997, Blood.
[6] J C Reed,et al. Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.
[7] R. Meadows,et al. Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.
[8] S. Korsmeyer,et al. Bax suppresses tumorigenesis and stimulates apoptosis in vivo , 1997, Nature.
[9] Andy J. Minn,et al. Bcl-xL forms an ion channel in synthetic lipid membranes , 1997, Nature.
[10] J. Xiang,et al. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[11] C. Milliman,et al. BID: a novel BH3 domain-only death agonist. , 1996, Genes & development.
[12] Junying Yuan,et al. Human ICE/CED-3 Protease Nomenclature , 1996, Cell.
[13] E. White,et al. Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K , 1996, Molecular and cellular biology.
[14] S. Korsmeyer,et al. BAX Is Required for Neuronal Death after Trophic Factor Deprivation and during Development , 1996, Neuron.
[15] S. Korsmeyer,et al. Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.
[16] R. Meadows,et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death , 1996, Nature.
[17] L. Frati,et al. bcl‐2/bax mRNA expression ratio as prognostic factor in low‐grade urinary bladder cancer , 1996, International journal of cancer.
[18] M. Rottenberg,et al. Bcl‐2, Bax and p53 expression in B‐CLL in relation to in vitro survival and clinical progression , 1996, International journal of cancer.
[19] G. Kroemer,et al. Mitochondrial control of nuclear apoptosis , 1996, The Journal of experimental medicine.
[20] John Calvin Reed,et al. Proapoptotic Protein Bax Heterodimerizes with Bcl-2 and Homodimerizes with Bax via a Novel Domain (BH3) Distinct from BH1 and BH2 (*) , 1996, The Journal of Biological Chemistry.
[21] J. Hunter,et al. Functional dissection of the human Bc12 protein: sequence requirements for inhibition of apoptosis , 1996, Molecular and cellular biology.
[22] K. Kinzler,et al. Analysis of mismatch repair genes in hereditary non–polyposis colorectal cancer patients , 1996, Nature Medicine.
[23] J. M. Boyd,et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. , 1995, Oncogene.
[24] T. Chittenden,et al. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. , 1995, The EMBO journal.
[25] J. Meijerink,et al. Bax mutations in cell lines derived from hematological malignancies. , 1995, Leukemia.
[26] S. Korsmeyer,et al. Bax-Deficient Mice with Lymphoid Hyperplasia and Male Germ Cell Death , 1995, Science.
[27] K. Franssila,et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. , 1995, Cancer research.
[28] Z. Oltvai,et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[29] B. Dörken,et al. Expression of the bcl‐2 gene family in normal and malignant breast tissue: Low bax‐α expression in tumor cells correlates with resistance towards apoptosis , 1995, International journal of cancer.
[30] L. Benítez-Bribiesca. [Apoptosis in the pathogenesis and treatment of disease]. , 1995, Gaceta medica de Mexico.
[31] John Calvin Reed,et al. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[32] S. Lowe,et al. p53-Dependent apoptosis suppresses tumor growth and progression in vivo , 1994, Cell.
[33] C. Borner,et al. The protein bcl-2 alpha does not require membrane attachment, but two conserved domains to suppress apoptosis , 1994, The Journal of cell biology.
[34] Z. Oltvai,et al. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax , 1994, Nature.
[35] John Calvin Reed. Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.
[36] D. Housman,et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.
[37] S. Korsmeyer,et al. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.
[38] R. Young,et al. Epitope tagging and protein surveillance. , 1991, Methods in enzymology.
[39] R. Schreiber,et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.
[40] Fred Winston,et al. Methods in Yeast Genetics: A Laboratory Course Manual , 1990 .
[41] S. Korsmeyer,et al. bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.
[42] P. Wernet,et al. Constitutive interleukin 2 production by the JURKAT human leukemic T cell line , 1982, European journal of immunology.